Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3
- 10 July 2013
- journal article
- Published by Springer Science and Business Media LLC in Angiogenesis
- Vol. 16 (4), 903-917
- https://doi.org/10.1007/s10456-013-9364-7
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Anti-angiogenesis therapy in cancer: Current challenges and future perspectivesCancer Letters, 2012
- Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): Mean overall survival (OS) estimation from a phase III trial (VELOUR).Journal of Clinical Oncology, 2012
- Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.Journal of Clinical Oncology, 2012
- STAT3 interacts directly with Hsp90IUBMB Life, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT SignalingPLOS ONE, 2011
- Structural Basis for Depletion of Heat Shock Protein 90 Client Proteins by DeguelinJNCI Journal of the National Cancer Institute, 2007
- Structure and Mechanism of the Hsp90 Molecular Chaperone MachineryAnnual Review of Biochemistry, 2006
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1αGenes & Development, 1998